Teva Pharmaceuticals Presents Data Showing UZEDY Improves Treatment Continuity, Reduces Hospitalizations And Cuts Healthcare Costs In Schizophrenia And Bipolar I Disorder

Teva Pharmaceuticals presented new real-world data indicating that its medication UZEDY improves treatment continuity for schizophrenia and reduces hospitalizations and emergency room visits in bipolar I disorder. The findings suggest that UZEDY can lead to over $1,000 in direct cost savings per patient per month by lowering healthcare resource utilization. These results were shared at the Psych Congress held from September 15 to 19, 2026, in New Orleans.